QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
GILD   59.89 (-0.37%)
NFLX   476.62 (-2.38%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
Log in
NASDAQ:GLMD

Galmed Pharmaceuticals Stock Forecast, Price & News

$3.98
+0.17 (+4.46 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.81
Now: $3.98
$4.04
50-Day Range
$3.06
MA: $3.36
$3.81
52-Week Range
$2.96
Now: $3.98
$7.38
Volume62,401 shs
Average Volume85,271 shs
Market Capitalization$84.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.
Read More
Galmed Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448
Employees17

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.04 million
Book Value$3.30 per share

Profitability

Net Income$-20,460,000.00

Miscellaneous

Market Cap$84.03 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$3.98
+0.17 (+4.46 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

How has Galmed Pharmaceuticals' stock price been impacted by COVID-19?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GLMD shares have decreased by 5.5% and is now trading at $3.98.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Galmed Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Galmed Pharmaceuticals
.

What stocks does MarketBeat like better than Galmed Pharmaceuticals?

Wall Street analysts have given Galmed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galmed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Galmed Pharmaceuticals
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.32) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.32).
View Galmed Pharmaceuticals' earnings history
.

What price target have analysts set for GLMD?

9 analysts have issued 1-year price targets for Galmed Pharmaceuticals' shares. Their forecasts range from $8.00 to $33.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $19.63 in the next year. This suggests a possible upside of 393.1% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a drop in short interest in the month of October. As of October 30th, there was short interest totaling 11,200 shares, a drop of 49.5% from the October 15th total of 22,200 shares. Based on an average trading volume of 72,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are sold short.
View Galmed Pharmaceuticals' Short Interest
.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 55, Pay $784.86k)
  • Mr. Yohai Stenzler, CFO & Controller (Age 37, Pay $155.34k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 35, Pay $165.43k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 53, Pay $242.52k)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 50, Pay $242.28k)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 37)

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Ibex Investors LLC (7.18%), Raymond James & Associates (1.08%), P.A.W. Capital Corp (0.95%), Phoenix Holdings Ltd. (0.69%), Morgan Stanley (0.62%) and Voss Capital LLC (0.59%).

Which major investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, and Voss Capital LLC.

Which major investors are buying Galmed Pharmaceuticals stock?

GLMD stock was bought by a variety of institutional investors in the last quarter, including Ibex Investors LLC, P.A.W. Capital Corp, Squarepoint Ops LLC, Morgan Stanley, Wedbush Securities Inc., and Phoenix Holdings Ltd..

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $3.98.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $84.03 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.